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Expression of Matrix Metalloproteinase-13 Is
Controlled by IL-13 via PI3K/Akt3 and PKC-d
in Normal Human Dermal Fibroblasts
Chikako Moriya1, Masatoshi Jinnin1, Keitaro Yamane1, Keishi Maruo1, Faith C. Muchemwa1,
Toshikatsu Igata1, Takamitsu Makino1, Satoshi Fukushima1 and Hironobu Ihn1
IL-13, a T helper type 2 cytokine, is reported to be increased in the tissue of patients with atopic dermatitis (AD).
In addition, chronic lichenified plaques in AD show thickened epidermis and dermis. We hypothesized that
IL-13 is involved in tissue remodeling by altering the expression of matrix metalloproteinases (MMPs). In this
study, we examined the MMP-related genes targeted by IL-13 in human dermal fibroblasts using a
complementary DNA microarray. We focused on the MMP-13 gene, which was identified as one of the MMPs
suppressed by IL-13. IL-13 downregulated both MMP-13 protein and mRNA expression. IL-13 suppressed MMP-
13 expression more effectively in the presence of protein kinase C (PKC)-d inhibitor, whereas IL-13 upregulated
MMP-13 in the presence of inhibitors of phosphoinositide 3-kinase (PI3K)/Akt pathway or Akt3-specific small
interfering RNA. Our results suggest that MMP-13 expression is negatively controlled by PI3K/Akt3 and
positively regulated by PKC-d in the presence of IL-13. Taken together, these findings indicate that IL-13 may
induce the formation of thickened dermis in AD by decreasing collagen degradation. Blockade of IL-13 signaling
cascades in AD patients may be a new therapeutic approach.
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INTRODUCTION
T helper type 2 responses are essential for the allergic
reaction and host defense against extracellular parasites. IL-4
and IL-13, both of which are major T helper type 2 cytokines,
mediate immune responses typically characterized by eosi-
nophilia, basophilia, mastocytosis, enhanced B-cell class
switching, antibody production, and plasma accumulation of
IgE and IgG1. IL-4 and IL-13 share a common receptor
subunit and have overlapping functions (LaPorte et al., 2008).
However, IL-13 might be the dominant effector cytokine
because IL-13 is much more abundant in vivo (Aleksza et al.,
2002; Kaminishi K et al., 2002; Terao et al., 2003; Tazawa
et al., 2004).
Recent studies have indicated that IL-13 is also associated
with the regulation of extracellular matrix (ECM) synthesis
and tissue remodeling (Wynn, 2004; Zheng et al., 2009). The
amount of ECM in the tissue might be controlled through a
balance among ECM production, ECM degradation by matrix
metalloproteinases (MMPs), and inhibition of MMPs by tissue
inhibitors of metalloproteinases (Visse and Nagase, 2003).
MMPs are a family of structurally related zinc-dependent
endopeptidases collectively capable of degrading essentially
all ECM components. Human MMP gene family can be
divided into subgroups of collagenases, gelatinases, strome-
lysins, membrane-type MMPs, and novel MMPs based on
their structure and substrate specificity (Birkedal-Hansen
et al., 1993b; Ka¨ha¨ri and Saarialho-Kere, 1997). Among
them, collagenases have a major role in the digestion of type I
collagen, the most abundant mammalian ECM in the skin
(Birkedal-Hansen, 1993a; Birkedal-Hansen et al., 1993b;
Sternlicht and Werb, 2001; Chakraborti et al., 2003). In this
study, we identified the MMP-related genes targeted by IL-13 in
human dermal fibroblasts using a complementary DNA (cDNA)
microarray. We then focused on the MMP-13 gene, which was
identified as one of the MMPs downregulated by IL-13 in the
microarray analysis. We clarified the mechanisms by which
IL-13 regulates MMP-13 expression in dermal fibroblasts.
RESULTS
Effects of IL-13 on MMP-related genes
The technique of differential hybridization of cDNA expres-
sion arrays was used to identify differences in the expression
pattern of genes between control and IL-13-treated fibro-
blasts. When the gene expression ratio (IL-13 treated/control)
of 41.5 or o0.67 was considered significant, among the
MMP-related genes, MMP-10, MMP-13, and MMP-16 were
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downregulated and only MMP-15 was upregulated by IL-13
(Table 1).MMP-1 andMMP-3 were slightly induced by IL-13,
but not significantly. Expression of tissue inhibitors of
metalloproteinases was not significantly affected by IL-13.
Thus, IL-13 may decrease the activity of ECM degradation by
altering the balance between MMPs and tissue inhibitors of
metalloproteinases.
Expression of MMP-13 is downregulated by IL-13 in human
dermal fibroblasts
MMP-13 is one of the collagenases that have a major role in
the digestion of type I collagen, as described above (Birkedal-
Hansen, 1993a; Birkedal-Hansen et al., 1993b; Sternlicht
and Werb, 2001; Chakraborti et al., 2003). MMP-13 mRNA
expression was also analyzed by quantitative real-time
PCR. The level of MMP-13 mRNA was reduced by the
treatment with IL-13 for 24 hours (Figure 1a). Then we
determined whether IL-13-mediated downregulation of
MMP-13 mRNA resulted in a decrease of the protein level.
Immunoblotting revealed that IL-13 decreased MMP-13
protein expression in a time-dependent manner (Figure 1b
and c). ELISA specific for MMP-13 also showed that MMP-13
concentration in culture supernatant was decreased by the
treatment with IL-13 for 48 hours (Figure 1d). These results
confirm the microarray data that the stimulation of
human dermal fibroblasts with IL-13 downregulates MMP-
13 expression.
IL-13 reduces MMP-13 expression via phosphoinositide
3-kinase/Akt signaling pathway
Subsequently, we investigated which signaling pathways
were involved in the IL-13-mediated MMP-13 downregula-
tion. First, cells were pretreated with phosphoinositide
3-kinase (PI3K) inhibitor LY294002 (Figure 2a) or Akt
inhibitor (Figure 2b) for 1 hour before the stimulation with
IL-13. IL-13 could not downregulate MMP-13 protein
expression in the presence of these PI3K/Akt inhibitors but
induced it significantly (Figure 2a and b). Interestingly, the
addition of these inhibitors in the absence of IL-13 decreased
basal MMP-13 expression. These results suggest that the PI3K/
Akt signaling pathway is essential for both basal MMP-13
expression and the reducing effect of IL-13 on MMP-13
expression.
Similar result was obtained by quantitative real-time PCR
examining the IL-13 effect on MMP-13 mRNA expression in
the presence of LY294002 or Akt inhibitor. IL-13 induced the
MMP-13 mRNA expression in the presence of these PI3K/Akt
inhibitors, rather than reducing it (Figure 2c).
In order to confirm whether IL-13 can activate the Akt
signaling pathway, whole-cell lysates were prepared from the
cells treated with IL-13, and immunoblotting was performed.
The phosphorylation levels of Akt at Thr 308 or Ser 473 were
increased after 3–6 hours of IL-13 treatment (Figure 2d). Thus,
IL-13 is likely to downregulate MMP-13 expression via
activation of the PI3K/Akt pathway.
Isoform-specific effect of Akt on IL-13-mediated MMP-13
downregulation
We then examined which isoform of Akt is associated with
the IL-13-mediated downregulation of MMP-13. To inhibit
each Akt isoform specifically, we used small interfering RNA
(siRNA) specific for Akt1/2 or Akt3. First, the knockdown
efficiency of siRNA was evaluated by immunoblotting
(Figure 3a and b). Expression of Akt1/2 or Akt3 was
downregulated by transfection of siRNA for Akt1/2
(Figure 3a) or Akt3 (Figure 3b), respectively, as compared
with control siRNA or transfection reagent only.
Then, MMP-13 expression in the cells transfected with
these siRNA in the presence or absence of IL-13 was analyzed
by immunoblotting. IL-13 significantly induced MMP-13
protein in the presence of Akt3 siRNA (Figure 3c and d),
which is consistent with the above result that IL-13 induced
Table 1. Effects of IL-13 on the expression profiles of MMP-related genes as measured with the cDNA microarray
Gene name Gene accession number Expression ratio
Matrix metalloproteinase-1 (interstitial collagenase) NM_002421 1.31
Matrix metalloproteinase-2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) NM_004530 0.89
Matrix metalloproteinase-3 (stromelysin 1, progelatinase) NM_002422 1.33
Matrix metalloproteinase-7 (matrilysin, uterine) NM_002423 0.98
Matrix metalloproteinase-10 (stromelysin 2) NM_002425 0.29
Matrix metalloproteinase-11 (stromelysin 3) NM_005940 1.05
Matrix metalloproteinase-13 (collagenase 3) NM_002427 0.34
Matrix metalloproteinase-15 (membrane inserted) NM_002428 1.65
Matrix metalloproteinase-16 (membrane inserted) NM_005941 0.08
Matrix metalloproteinase-19 NM_022790 0.79
Tissue inhibitor of metalloproteinase-2 NM_003255 1.13
Tissue inhibitor of metalloproteinase-3 (Sorsby fundus dystrophy, pseudoinflammatory) NM_000362 0.73
Abbreviations: cDNA, complementary DNA; MMP, matrix metalloproteinase.
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MMP-13 expression in the presence of PI3K/Akt inhibitors
(Figure 2). On the other hand, in the presence of Akt1/2
siRNA, IL-13 did not alter MMP-13 expression. Considering
that Akt3 siRNA and PI3K/Akt inhibitors had similar effects on
MMP-13 expression, Akt3 may be the main pathway that
mediates the IL-13 effect on MMP-13 expression.
PKC-d inhibitor amplified the reducible effect of IL-13 on
MMP-13 expression
As shown above, PI3K/Akt inhibitors downregulated
basal MMP-13 expression in the absence of IL-13, whereas
PI3K/Akt inhibitors upregulated the expression of MMP-13 in
the presence of IL-13 (Figure 2). Conversely, IL-13 decreased
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Figure 1. IL-13 downregulates matrix metalloproteinase (MMP)-13 at a transcriptional and post-transcriptional level in human dermal fibroblasts. Cells were
incubated in the presence or absence of IL-13 (10 ngml1). (a) Real-time PCR for MMP-13 was performed. The value in untreated cells was set at 1.
(b) Conditioned media and cell lysates were subjected to immunoblotting with MMP-13 and b-actin antibody. (c) MMP-13 protein levels quantitated by
scanning densitometry and corrected for b-actin are shown relative to the level in untreated cells (1.0). Data are expressed as the mean±SD of five independent
experiments. (d) Cells were incubated in serum-free medium for 48 hours in the presence or absence of IL-13 before collection of medium. Specific ELISA for
detecting MMP-13 levels was performed as described in ‘‘Materials and Methods’’. *Po0.05 as compared with the value in untreated cells.
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Figure 2. Effect of LY294002 or Akt inhibitor on IL-13-mediated matrix metalloproteinase (MMP)-13 downregulation. (a, b) Human dermal fibroblasts were
treated with 30mM LY294002 (a) or 10mM Akt inhibitor (b) for 1 hour before the addition of IL-13 (10 ngml1) for 24 hours. Immunoblotting was performed as
described in Figure 1b. One experiment representative of five independent experiments is shown. (c) Cells were treated with LY294002 (30mM) or Akt inhibitor
(10mM) 1 hour before the addition of IL-13 (10 ngml1) for 24 hours. MMP-13 mRNA levels were determined by quantitative real-time PCR as described in
Figure 1a. (d) Human dermal fibroblasts were treated with IL-13 (10 ngml1) for the indicated time. Cell lysates were subjected to immunoblotting with
antibodies for phosphorylated Akt (Thr 308 or Ser 473). One experiment representative of three independent experiments is shown. *Po0.05 as compared with
the value in untreated cells.
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MMP-13 expression in the absence of PI3K/Akt inhibitors,
whereas IL-13 upregulated it in the presence of the inhibitors.
To explain the paradoxical effects of IL-13 and PI3K/Akt
inhibitors, we expected the presence of another downstream
target of IL-13, which competes with PI3K/Akt. Pretreatment
of cells with the p38 inhibitor SB203580 did not affect the
IL-13-mediated downregulation of MMP-13 mRNA (data not
shown). On the other hand, in the presence of Rottlerin, a
selective protein kinase C (PKC)-d inhibitor, IL-13 decreased
MMP-13 expression more effectively than in the absence of
Rottlerin (Figure 4a). In the absence of IL-13, basal MMP-13
expression was not significantly affected by Rottlerin. Thus,
PKC-d is thought to have an inducible effect under the
stimulation with IL-13.
It is generally accepted that inactive PKC isoforms are
located in the nucleus and translocated to the plasma
membrane and/or cytoskeleton after activation (Mochly-
Rosen et al., 1990; Tourkina et al., 2001). To examine
the activation of PKC-d by IL-13, immunofluorescence
microscopy using anti-PKC-d antibody was performed. The
result revealed that PKC-d was translocated to the plasma
membrane in IL-13-treated fibroblasts (Figure 4b).
Taken together, our results suggest that IL-13 activates
both PI3K/Akt and PKC-d. The effect of PKC-d on MMP-13
expression was opposite to that of PI3K/Akt3, probably
competing with it. Considering that IL-13 stimulation
results in MMP-13 downregulation, PI3K/Akt3 may be
dominant to PKC-d (Figure 5). Based on this hypothetical
model, in the presence of PI3K/Akt inhibitors, the addition
of IL-13 can increase MMP-13 expression because PKC-d is
still activated, and the reducing effect of IL-13 on MMP-13
expression is amplified in the presence of Rottlerin. On the
other hand, in the absence of IL-13, PI3K/Akt inhibitors
decrease basal MMP-13 expression because PI3K/Akt is
essential for basal MMP-13 expression.
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Figure 3. Effect of small interfering RNA (siRNA) specific for each Akt isoform on IL-13-mediated matrix metalloproteinase (MMP)-13 downregulation.
(a, b) Cells were transfected with siRNA specific for Akt1/2 (siAkt1/2) or Akt3 (siAkt3). Immunoblotting was performed as described in Figure 1b. The results in
the cells treated with control siRNA or transfection reagent only are also shown as controls. (c, d) Cells were transfected with siRNA specific for Akt isoform
as described in Figure 3a and b. Then cells were incubated with or without IL-13 for 24 hours (c). The levels of MMP-13 protein quantitated by scanning
densitometry and corrected for the levels of b-actin in the same samples are shown relative to the level in cells without IL-13 treatment (1.0) (d). *Po0.05
as compared with the value in cells without IL-13 treatment.
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Figure 4. Activation of protein kinase C (PKC)-d by IL-13 in human
dermal fibroblasts. (a) Human dermal fibroblasts were treated with 3 mM
Rottlerin for 1 hour before the addition of IL-13 (10 ngml1) for 24 hours.
Conditioned media or cell lysates were subjected to immunoblotting with
antibody for matrix metalloproteinase (MMP)-13 or b-actin, respectively.
(b) The subcellular translocalization of endogenous PKC-d by IL-13 was
visualized by immunofluorescence microscopy. Human dermal fibroblasts
were serum-starved for 24 hours and incubated in the presence or absence
of IL-13 (10 ngml1) for 1 hour. Punctate stainings of PKC-d are indicated
by arrows.
658 Journal of Investigative Dermatology (2011), Volume 131
C Moriya et al.
Expression of MMP-13 Is Controlled by IL-13
DISCUSSION
In this article, we have presented several major findings. First,
IL-13 can alter the expression of MMP-related genes by
cDNA microarray analysis. Second, expression of MMP-13 is
downregulated by IL-13 in human dermal fibroblasts. Third,
inhibitors of the PI3K/Akt pathway decreased basal MMP-13
expression. Finally, IL-13 upregulated MMP-13 expression in
the presence of PI3K/Akt inhibitors or Akt3-specific siRNA,
whereas IL-13 suppressed MMP-13 more effectively in the
presence of Rottlerin.
Akt is present in all eukaryotes and is involved in a wide
variety of cellular functions, including proliferation, cell
survival, and differentiation (Cho et al., 2001; Bernal-
Mizrachi et al., 2004). In mammals, three isoforms—Akt1/
PKBa, Akt2/PKBb, and Akt3/PKBg—share a high degree of
amino-acid identity and are activated by similar pathways in
a PI3K-dependent manner (Brazil et al., 2004). However,
each isoform may have specific functions. For example, Akt3,
but not Akt1, mediates MMP-13 upregulation induced by IL-1
or oncostatin-M in cultured human chondrocytes (Litherland
et al., 2008). Our study suggests that Akt3 may be the key
molecule in downregulation of MMP-13 as well as upregulation.
The PKC family of proteins comprises at least 10 isozymes
with diverse functions that are involved in numerous important
cellular processes (Jimenez et al., 2001). Studies have
established that the activation of PKC is necessary for the
stimulation of gene expression in response to various cytokines
and that several cellular responses to IL-13 are regulated by a
PKC-dependent signal-transduction pathway. For example,
PKC-d and -z mediate IL-4/IL-13-induced germline e-transcrip-
tion in human B cells (Ikizawa et al., 2001).
Our hypothetical scheme is shown in Figure 5. In the
presence of IL-13, the effect of PKC-d on MMP-13 expression
was opposite to that of PI3K/Akt3. We previously reported
that IL-13 stimulates the transcription of tenascin-C and a2(I)
collagen genes via the PI3K/Akt and PKC signaling pathway
(Jinnin et al., 2004, 2006). Interestingly, in the regulatory
mechanism of tenascin-C by IL-13, both PI3K/Akt and PKC
had positive effects on tenascin-C expression. PI3K/Akt and
PKC signaling activated by IL-13 may have a major role in
both ECM production and degradation, cooperating or
competing with each other. On the other hand, MMP-13
expression was unchanged by inhibitors of p38 mitogen-
activated protein kinase in human dermal fibroblasts in the
presence of IL-13 (data not shown), although the activity of
p38 mitogen-activated protein kinase was reported to be
essential for MMP-13 induction by transforming growth
factor-b in gingival fibroblasts cultured in collagen gel
(Ravanti et al., 1999). This discrepancy may be explained
by the speculation that p38 mitogen-activated protein
kinase activation is essential for MMP-13 upregulation,
whereas downregulation of MMP-13 is mediated by PI3K/
Akt and PKC.
In atopic dermatitis (AD), chronic lichenified plaques
show thickened epidermis and dermis. In the thickened
dermis, deposition of ECM such as type I collagen or
tenascin-C is found (Toda et al., 2003). Therefore, fibrosis
occurs in chronic AD skin lesions by increased ECM
deposition, including type I collagen or tenascin-C, and the
fibrosis may have some role in the pathogenesis of AD.
However, the mechanisms of the fibrosis in AD are still
unknown. In addition, in AD patients, higher numbers of
IL-13-positive cells are seen in skin lesions, reflecting
T helper type 2 inflammation of this disease (Hamid et al.,
1996). In IL-13 transgenic mice, the skin showed thickening
of the epidermal and dermal layers (Zheng et al., 2009),
which is similar to AD skin. IL-13 signaling at sites of T helper
type 2 inflammation of AD skin may be the key participant
that stimulates ECM production, such as type I collagen or
tenascin-C via PI3K/Akt or PKC, as described above. Also,
IL-13-mediated MMP-13 downregulation may accelerate
ECM deposition in AD skin by reducing ECM degradation
activity. Our study contributes to a better understanding of
the mechanisms of fibrosis in AD skin. Controlling MMP-13
expression via the balance of PI3K/Akt3 and PKC-d is a new
therapeutic approach to chronic and untreatable AD.
There were some limitations of our study. First, LY294002
or Akt inhibitor increased MMP-13 expression more than
two-fold in the presence of IL-13 (Figure 2c), whereas Akt3-
specific siRNA increased MMP-13 only up to 20% (Figure
3d). This discrepancy may be explained by the differences in
the method (e.g., immunoblotting or real-time PCR) and
reagent (kinase-specific inhibitor or siRNA) used in each
experiment. Otherwise, this may indicate the synergistic
effect of Akt1/2 and Akt3 to downregulated MMP-13
expression. Furthermore, although our results indicated that
the PI3K/Akt3 pathway mediates strong suppression of MMP-
13 expression by IL-13 and that inhibition of the pathway
leads to increased MMP-13 expression that exceeds the
Basal expression IL-13 stimulation
IL-13
PI3K/Akt
(Strong suppressor)
PKC-δ
(Weak inducer)PI3K/Akt
(Weak inducer)
MMP-13 MMP-13
Figure 5. Diagram summarizing major pathways that are involved in
matrix metalloproteinase (MMP)-13 expression. In the absence of IL-13 (left),
basal expression of MMP-13 is positively controlled by PI3K/Akt. Thus, PI3K/
Akt inhibitors decrease basal MMP-13 expression. In the presence of IL-13
(right), PI3K/Akt and PKC-d are activated. PI3K/Akt3 has a reducing effect
and PKC-d has an inducing effect on MMP-13 expression. Because PI3K/Akt3
is dominant over PKC-d, IL-13 stimulation results in downregulation of
MMP-13. Addition of PI3K/Akt inhibitors increases MMP-13 expression
because PKC-d is still activated, whereas Rottlerin causes a further decrease
of MMP-13.
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amplitude of the ‘‘native’’ inhibitory action of the cytokine,
there may be a more complex mechanism than that
illustrated in Figure 5. For example, PI3K/Akt3 may interact
with PKC-d or other signaling pathways directly or indirectly
to mediate the effect of IL-13. Further studies are needed to
clarify these points.
MATERIALS AND METHODS
Regents
Recombinant human IL-13 was obtained from R&D Systems
(Minneapolis, MN). The antibody for MMP-13 was purchased from
Lab Vision (Fremont, CA). Primary antibodies against actin, Akt1/2,
Akt3, phosphorylated Akt (Thr308 and Ser473), and PKC-d were
from Santa Cruz Biotechnology (Santa Cruz, CA). Akt inhibitor was
from Calbiochem (La Jolla, CA). Rottlerin was from Merck
(Darmstadt, Germany). Lipofectamine RNAiMAX transfection regent
was purchased from Invitrogen Corporation (Carlsbad, CA).
Cell cultures
Human dermal fibroblasts were obtained by skin biopsy from five
healthy donors as described previously (Ihn et al., 1996, 1997). All
biopsies were obtained with institutional review board approval and
written informed consent according to the Declaration of Helsinki
principles. Primary explant cultures were established in 25 cm2
culture flasks in modified Eagle’s medium supplemented with 10%
fetal calf serum, 1% penicillin, streptomycin, and amphotericin B
(Gibco, Carlsbad, CA). Monolayer cultures were maintained at 37 1C
in 5% CO2 in air. Fibroblasts between the third and seventh
subpassages were used for experiments.
Microarray
The cDNA microarray hybridization experiments were performed using
Intelligene Human Cancer CHIP, version 2.1 (Takara, Tokyo, Japan)
according to the manufacturer’s directions. The protocol used and a
complete listing of the nearly 800 genes related to cancer on the Human
Cancer CHIP are available on the Web. An B300-bp cDNA region of
each gene, which has minimal homology with other genes registered in
the cDNA database, is spotted on this DNA chip. Poly (A)þ mRNA was
isolated and used to prepare cDNAs that were fluorescently labeled
with either Cy3 (IL-13 untreated) or Cy5 (IL-13 treated) fluorescent dye.
Samples were mixed and applied to DNA microarrays. The arrays were
scanned using ScanArray (GSI Group Japan Corporation, Tokyo, Japan),
and the data were analyzed using Quant Array (BM BIO, Tokyo, Japan)
(Hishikawa et al., 2001). A gene expression ratio (Cy5/Cy3) of41.5 or
o0.67 was considered significant.
Western blotting analysis
Human dermal fibroblasts were cultured until they were subcon-
fluent. Cells were serum starved, and then the medium was
collected. The medium was concentrated 10 times using Amicon
Ultra (Millipore, Billerica, MA). The remaining cells were washed
with cold phosphate-buffered saline twice and lysed in lysis buffer
(Denaturing Cell Extraction Buffer, Biosource, Camarillo, CA)
supplemented with 1mM phenylmethylsulfonyl fluoride and pro-
tease inhibitor cocktail (Sigma, St Louis, MO). Cell lysates were
quantitated using the BCA protein assay kit (Thermo Fisher Scientific,
Rockford, IL) according to the manufacturer’s protocol. Equal
amounts of protein were loaded and separated on 10% SDS-PAGE
and then transferred to a nitrocellulose membrane. Nonspecific
binding to the membrane was blocked for 1 hour at room
temperature with 5% nonfat milk or 1% fetal albumin. Membranes
were incubated overnight at 4 1C with the primary antibodies diluted
as follows: MMP-13 (1:200), Akt1/2 (1:200), Akt3 (1:200), phos-
phorylated Akt at Thy308 (1:500), and phosphorylated Akt at Ser473
(1:500). Then membranes were incubated with secondary antibody
for 1 hour at room temperature. The immunoblots were developed
using the enhanced chemiluminescence detection system from
Amersham Biotech (Piscataway, NJ). Image analysis was performed
using ImageJ software (National Institutes of Health, Bethesda, MD).
RNA isolation and reverse transcription
Total RNA was extracted from cultured human dermal fibroblasts
using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. The first-strand cDNA was synthe-
sized using the PrimeScript RT reagent Kit (Takara) with both
oligo-dT primer and random hexamers.
Quantitative real-time PCR
Quantitative real-time PCR with a Takara Thermal Cycler Dice
(TP800) was performed using primers and templates mixed with the
SYBR Premix Ex Taq Kit (Takara). Primer sets for MMP-13 and 18S
ribosomal (r18S) RNA were purchased from Takara. Primer sets were
prevalidated to generate single amplicons. Two microliters of first-
strand cDNA product was used for amplification in duplicate in a
25 ml reaction solution containing 12.5 ml of SYBR Green/Fluorescein
PCR master mix and 0.5 ml of each primer. DNA was amplified for
45 cycles of denaturation for 5 seconds at 95 1C and annealing for
30 seconds at 66 1C. Data generated from each PCR reaction were
analyzed using the Thermal Cycler Dice Real Time System, version
2.10B (Takara). Specificity of reactions was determined by melting
curve analysis. Data were analyzed using the comparative Ct
method. The r18S RNA was used as a normalizer.
The transient transfection
siRNAs against Akt1/2 and Akt3 were purchased from Santa Cruz
Biotechnology. Human dermal fibroblasts were plated in six-well
plates. At 20% confluence, cells were transfected with siRNA for
Akt1/2, Akt3, or non-targeting control RNA mixed with Lipofecta-
mine RNAiMAX transfection reagent and incubated without media
change for 48 hours.
Immunofluorescence microscopy
Dermal fibroblasts were grown in four-well LAK TEK chambers (Nunc,
Naperville, IL) to subconfluence as described above. After 24hours of
serum starvation, cells were fixed with 3.7% formaldehyde, permeabi-
lized with 0.5% Triton X-100 in phosphate-buffered saline, and blocked
with 10% fetal calf serum in 0.5% Triton X-100 in phosphate-buffered
saline. Cells were stained with anti-PKC-d antibody as the primary
antibody, washed, and incubated with FITC-conjugated secondary
antibody. To visualize the antibody staining, a fluorescence microscope
(Carl Zeiss Meditec, Dublin, CA) was used (Asano et al., 2004).
Statistical analysis
Data presented as bar graphs are the meansþ SD of at least three
independent experiments. Statistical analysis was performed using the
Mann–Whitney U-test. P-values o0.05 were considered significant.
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